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The pathogenesis of cancer is not an all-
or-none phenomenon, but rather a
consequence of multiple events. Peyton
Rous recognized this notion more than
70 years ago when he coined the term
“cancer progression” to describe how
“tumors went from bad to worse,” in refer-
ence to experiments observing conver-
sion of virus-induced benign papillomas
to carcinomas (Shope and Hurst, 1933).
Leslie Foulds extended the concept in
his remarkable set of experiments char-
acterizing mouse carcinogenesis, lead-
ing him to realize that sequential cellular
alterations were required to generate
cancer (Foulds, 1954).
Much has been learned from the
study of skin carcinogenesis. The multi-
step story of cancer was put on firmer
footing with the two-step “initiation-pro-
motion” model of chemically induced
skin carcinogenesis (Berenblum and
Haran, 1955). In these ageless experi-
ments, a single small dose of a mutagen,
an initiator, irreversibly (genetically)
altered the state of the cell. This phase is
necessary but insufficient to produce
tumors. Tumors are produced through
promotion by repeated applications of
inflammatory compounds to the recep-
tive initiated site, producing inflamma-
tion, cell proliferation, and other effects
that are reversible. An oversimplistic
interpretation of two-step carcinogenesis
is: (1) initiation by activating or disabling
mutations in molecules that regulate the
cellular circuits and capacitors control-
ling cell division, survival, and senes-
cence, and (2) promotion by cellular and
extracellular signals leading to immortal-
ized cells that are resistant to growth-
inhibitory signals and apoptosis. The
molecular details of cancer pathogene-
sis are rapidly being unraveled at the cel-
lular level, but what is missing in this
deconstruction is how the physiologic
responses of the host fit in.
When one moves from the reduc-
tionist cellular point of view to a more
global view of carcinogenesis and can-
cer pathogenesis, the innate immune
system emerges as an important player
at the interface between the host, malig-
nant transformation, and cancer pro-
gression. The immune system has been
called a “double-edged sword,” describ-
ing its ability on the one hand to fight
infectious pathogens and on the other
to produce autoimmunity. This metaphor
applies to the immune system’s
relationship to cancer—the immune sys-
tem can destroy tumors, and yet para-
doxically also promotes and sustains
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The role of the immune system in early epithelial carcinogenesis:
B-ware the double-edged sword
Cancer is commonly described as a disease of genetic mutations. However, epidemiologic and clinical evidence points to
the important but multifaceted role of the host.The immune system has something to say about cancer evolution through
promotion of malignancy by inflammatory myeloid cells of the innate immune system. In a report in this issue of Cancer
Cell, B cells are implicated as key players in the regulation of chronic inflammation that promotes early events in epithelial
carcinogenesis. These are surprising observations, linking antibodies of the adaptive immune system to innate immune
responses that drive epithelial carcinogenesis.
Figure 1. Model of antibody-
mediated inflammation dri-
ving early skin carcinogenesis
Naive B cells are activated by
skin-derived antigens (HPV16
E6, E7, and/or degraded
products of keratinocytes
and extracellular matrix?) in
the presence of CD4 T cells,
and differentiate into memo-
ry B cells and plasma cells.
Antibodies produced by
plasma cells stimulate resi-
dent myeloid cells (e.g.,
macrophages) in the dermis
via activating Fc receptors to
secrete VEGF, MMPs, and
other inflammatory media-
tors, followed by further
recruitment of innate immune
cells. Chronic inflammation
mediated by interaction of
antibodies with innate
immune cells facilitates can-
cer development.
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cancer. The rules for these choices are
unclear.
A body of experimental and clinical
evidence has emerged over the last
decade showing that the immune system
can prevent the development of incipient
epithelial, mesenchymal, and lymphoid
malignancies (Dunn et al., 2002). Mouse
strains deficient in various arms of the
immune system develop cancers at ele-
vated rates compared to congenic
immune-competent mice. The cancers
that develop in immune-deficient mice are
very immunogenic when transplanted
back to immune competent mice, com-
pared to the poor immunogenicity of
spontaneous tumors arising directly in
immune-competent mice.These observa-
tions suggest that tumors that arise in
competent mice are shaped or edited by
the immune system, evolving to escape
further immune pressures. The details of
immune surveillance have yet to be
solved, but seem to involve lymphocytes,
cytotoxic granules produced by lympho-
cytes, and signaling through type II inter-
feron receptors. How adaptive immune
cells (B cells and T cells with their remark-
ably specific receptors) and innate
immune cells (natural killer and related
cells, and myeloid lineage cells) con-
tribute to cancer surveillance remains to
be elucidated. We can say that the
immune system serves as a tumor sup-
pressor at the level of the host.
Furthermore, immune therapies have
become standard components of treat-
ment for more advanced cancers, includ-
ing cytokines, monoclonal antibodies, and
T cells (crucial for the efficacy of allogene-
ic hematopoietic stem cell transplants).
Immunity against cancer provides one
edge of the blade that fights cancer.
The other edge of the blade is the
role of the immune system in initiating
and promoting cancer (reviewed by
Balkwill et al., 2005). Clinical observa-
tions recorded through the centuries
have pointed to the strong association of
chronic inflammation and cancer. The
great pathologist Rudolf Virchow recog-
nized the association between inflamma-
tion and cancer and speculated that
inflammation might play a role in tumor
pathogenesis.Tumors arise in the context
of stroma, which includes lymphocytes,
myeloid cells (macrophages, dendritic
cells, granulocytes, eosinophils, mast
cells, and endothelial cells), fibroblasts,
and connective tissue. Myeloid cells have
drawn special interest because of their
remarkable ability to produce a rich array
of factors and small chemicals that can
influence tumorigenesis both negatively
and positively (Nathan and Sporn, 1991).
Upon activation, macrophages express
factors that promote growth and survival
of tumors, angiogenesis, tissue invasion,
and metastases (Table 1).
Because of the strong link between
inflammation and cancer, most of the
focus of researchers has been, appropri-
ately, on cells and products of the innate
immune system. Activated innate immune
cells can interfere with T cell responses to
cancer. Macrophages can: (1) inhibit
antigen presentation by dendritic cells,
directly suppress T cell responses, and
indirectly downregulate immunity by
inducing suppressor (regulatory) T cells
through effects of IL-10 and TGF-β; (2)
convert tryptophan to kynurenine through
indoleamine-2,3-dioxygenase, disabling T
cells; (3) deplete L-arginine by arginase
leading to loss of CD3 ζ chain of the T cell
receptor with impairment of signaling; (4)
produce nitric oxide (NO) by inducible
nitric oxide synthase (iNOS), creating
nitrate adducts on tyrosine which block
signaling from the IL-2 receptor; and (5)
produce both superoxide and NO, which,
under conditions of limited arginine avail-
ability, form the highly reactive oxidizing
molecule peroxynitrite, instigating T cell
apoptosis. Thus, ongoing inflammatory
responses have the capacity to profound-
ly alter the ability of the host to mount
adaptive immune responses locally within
the inflammatory stroma of tumors.
Immunologists have long viewed the
adaptive immune system, and particular-
ly T cells, as central participants in immu-
nity against cancer. This one-sided view
has been repeatedly challenged through
the years. Two relevant publications are
worth mentioning from the many papers
on this topic. A report from Daniel et al.
examined the role of CD4+ cells in epithe-
lial tumors of transgenic mice expressing
HPV16 early region genes (including E6
and E7) under a human keratin 14 pro-
moter/enhancer (Daniel et al., 2003).
HPV16 transgenic mice deficient in CD4
had a delay in tumor progression, albeit
small, associated with decreased inflam-
mation manifested as reduced infiltration
of neutrophils and MMP-9 activity. These
findings suggest a role for CD4+ cells in
tumor progression, an observation that
makes sense from the perspective of
CD4+ T cells or NKT cells orchestrating
inflammatory responses in their role as
helper cells. In a second relevant study,
Siegel et al. observed acceleration of
tumor progression in transgenic mice
expressing a mutant ras oncogene treat-
ed with a chemical tumor promoter fol-
lowing immunization with a mutated ras
peptide (Siegel et al., 2000). Intriguingly,
in the Siegel model, accelerated tumors
were associated with the presence of
antibodies against mutant ras protein.
Now, in this issue of Cancer Cell, de
Visser and colleagues come along with
the compelling evidence that soluble fac-
tors, probably antibodies, produced by B
cells are the culprit in promoting de novo
skin tumors in the HPV16 model (Figure
1) (de Visser et al., 2005). They demon-
strate that HPV16 mice crossed to recom-
binase-deficient RAG1−/− mice, which
have a complete absence of mature B
cells and T cells, show a marked delay in
early tumorigenesis associated with
reduced inflammation. What is interesting
is the finding that adoptive transfer of B
cells or sera from wild-type transgenic
mice restores inflammatory cell infiltrates,
angiogenesis, epithelial hyperplasia, and
tumor progression in premalignant
lesions (Figure 1). The observations are
novel with regard to linking soluble B cell
products to inflammation in early steps in
cancer development, addressing an old
observation by tumor immunologists
relating antibody responses (especially
immune complexes with antigen, which
are particularly proinflammatory) to accel-
erated growth of transplanted tumors.The
results strongly point to antibodies in
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Table 1. Macrophage-produced factors with potential to influence tumorigenesis
Biologic effects Factors and molecules
Growth and survival Basic FGF, EGF, hepatocyte growth factor, PDGF, IL-6, TNF, 
polyamines, PGE2
Angiogenesis VEGF, MMP-9, IL-1, IL-8, urokinase-type plasminogen activator 
(uPA), CXCL1, CXCL8, HIF-1α, HIF-2α, PGE2
Tissue invasion and metastases Chemokines, PGE2, matrix metalloproteinases, uPA, plasmin
Mutations Superoxide, peroxynitrite
Inhibition of T cell responses IL-10, TGF-β, indoleamine-2,3-dioxygenase, PGE2, superoxide, 
peroxynitrite, arginase
CANCER CELL : MAY 2005 405
establishing inflammation to promote ear-
lier steps in cancer progression of skin
previously “initiated” by the HPV16 trans-
genes. In contrast to the results of Daniel
et al., CD4+ cells were not required for this
early tumor promotion. The discrepancy
may relate to effects of different cells of
the adaptive immune system at different
stages of tumor development and pro-
gression. For Daniel et al., deficiency of
CD4 cells correlated with a trend toward
earlier lesions (hyperplasia versus dys-
plasia at 6 months) and a small but signif-
icant difference in incidence of squamous
cell tumors at a later stage of tumor pro-
gression (at 12 months).
The observations of de Visser et al.
raise a number of questions:
• Are antibodies mediating this tumor
promotion, or might B cell-derived
chemokines, cytokines, or other soluble
molecules?
• If the active principle is antibody,
what is the specificity? Cutaneous bacter-
ial symbionts or pathogens, autoantigens
(including the HPV transgene products),
or products of mutations in transformed
cells? Tantalizingly, de Visser et al. briefly
relate unpublished observations that early
development of tumors is not different in
germ-free mice, suggesting that bacteria
are not driving antibodies.
• If antibodies, what are the mecha-
nisms for eliciting inflammation (Figure 1)?
Signaling through activating Fc receptors
on myeloid cells to initiate production of
inflammatory molecules? Complement
activation producing the anaphylatoxins
C3a and C3b to drive inflammation
through complement receptors on myeloid
cells? Both?
• Do T cells play a role in the observa-
tions? Importantly, the authors could not
rule out the complete absence of T cells
in their adoptive transfer experiments.
If antibodies are found to be the
mediators of the inflammatory response
early on during carcinogenesis in this
model, the answers to these questions
will become relevant to developing strate-
gies for prevention of cutaneous epithelial
tumors and possibly other cancers.
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Pancreatic cancer likely reflects a model
type of cancer displaying essentially all
molecular and biological cancer hall-
marks, such as genetic and epigenetic
alterations, chromosomal instability, pro-
gression from preneoplastic lesions to
an invasive and metastatic phenotype,
and virtually complete resistance to any
therapeutics tested so far. Along with
this depressing clinical situation goes a
considerable insight into the genetic and
cellular events from the earliest preneo-
plastic lesions, found in as many as 50
percent of normal pancreata in the
elderly population (Hruban et al., 2004),
to late metastatic disease (Figures 1A
and 1B). Due to significant progress in
the development of genetically engi-
neered murine models of human can-
cers (Van Dyke and Jacks, 2002),
mouse models of pancreatic cancer
have evolved that mimic the human dis-
ease genetically and morphologically in
an astonishing way. By conditional acti-
vation of endogenously expressed
oncogenic KrasG12D in the pancreas of
mice, Hingorani, Tuveson, and col-
leagues were able to induce preneo-
plastic lesions that eventually progress
to invasive and metastatic pancreatic
adenocarcinoma (Hingorani et al., 2003
and Figure 1C). However, invasive and
metastatic cancer developed at a
considerable advanced age in mice,
revealing a rather slow progression con-
sidering that PanIN-3 lesions can
already be detected at the age of 4–6
months to the time of full-blown pancre-
atic cancer at around 12–15 months of
age. By introducing tissue-specific defi-
ciency of the Ink4a/Arf tumor suppres-
sors, often mutated or silenced in
Chromosomal instability in mouse metastatic pancreatic cancer—
it’s Kras and Tp53 after all
A human pancreatic cancer progression model from intraepithelial neoplasia to ductal adenocarcinoma has been pro-
posed. This process has been modeled in the mouse by activation of mutant Kras in pancreatic progenitor cells. In this
issue of Cancer Cell, Hingorani et al. (2005) present a modification of their initial model by introducing a mutant Tp53.This
combination of genetic alterations leads to rapid and increased frequency of neoplasia progression resulting in pancreat-
ic cancers that manifest chromosomal instability in the presence of apparent intact telomeres. These findings introduce
Tp53-mediated chromosomal instability as key event for carcinoma development in this mouse model.
